Innovative GFAP blood biomarker test expands Labcorp's portfolio of tests for diseases including Alzheimer's disease, multiple sclerosis, glioblastoma and brain injuries BURLINGTON, N.C., April 15, ...

A new blood test from Labcorp could potentially help cancer patients begin the most efficient treatments as early as possible. The Plasma Focus liquid biopsy requires only a standard blood draw to run ...

Please provide your email address to receive an email when new articles are posted on . Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Labcorp Holdings (NYSE:LH) launched the first FDA cleared ...

In February 2026, Labcorp announced nationwide availability of the Elecsys pTau-181 blood test, the first FDA-cleared primary-care tool to aid in ruling out Alzheimer’s disease by identifying ...

BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® ...

(RTTNews) - Labcorp (LH) Wednesday has announced a significant expansion of its precision oncology offerings with two advanced diagnostic solutions to improve cancer detection and treatment decisions.

Labcorp Holdings, Inc. LH has announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio — the first FDA-cleared blood-based in-vitro diagnostic (IVD) test to assist in ...